System: You are provided with a paragraph. Your goal is to automatically identify the most relevant tasks based on the content of the paragraph and generate an example of entailment (if the task conclusion can be logically inferred from the paragraph) and a different example of non-entailment (if it is unclear or the opposite conclusion is true). 

Step 1: Read the paragraph carefully. 
Step 2: Automatically decide which tasks are relevant based on the paragraph’s content. Relevant tasks may include, but are not limited to: 
    - Topic Classification 
    - Risk Classification
    - Sentiment Classification 
    - Tone Classification
    - Event Detection 
    - Entity Recognition 
    - Geographical Recognition 
    - Trend Detection 
    - Intent Detection 
    - Sector Identification 
    - Impact Classification 
    - Tense Identification (Past, Present, Future) 
    - Uncertainty Identification 

Step 3: For each relevant task you identify, generate two clear and concise examples whose labels match common practices for the task at hand: one for entailment and one for non-entailment. The example should speak about the text at the 3rd person. 
Step 4: Output the results in the following JSON format:

{
    'relevant_tasks': [
        {
            'task': <The automatically selected relevant task>,
            'examples': [
                {
                    'input': <The entailment example based on the paragraph>,
                    'label': 'entailment',
                },
                {
                    'input': <The non-entailment example (neutral or contradiction) based on the paragraph>,
                    'label': 'non-entailment',
                }
            ]
        },
        ...
    ]
}
User: We are involved in numerous patent litigations in which we challenge the validity or enforceability of innovator companies’ listed patents and/or their applicability to our generic and/or biosimilar pharmaceutical products, as well as patent infringement litigation in which other generic/biosimilar companies challenge the validity or enforceability of our patents and/or their applicability to their generic/biosimilar pharmaceutical products, and therefore settling patent litigations has been and is likely to continue to be an important part of our business. As part of the Medicare Prescription Drug and Modernization Act of 2003, companies, including us, are required to file with the FTC and the DOJ agreements entered into between branded and generic and/or biosimilar pharmaceutical companies related to the manufacture, marketing and sale of generic/biosimilar versions of branded drugs for their review. In June 2013, the U.S. Supreme Court in its decision in FTC v. Actavis determined that “reverse payment” patent settlement agreements between brand and generic/biosimilar companies could violate the antitrust laws. The Supreme Court held that such settlement agreements are neither immune from antitrust attack nor presumptively illegal but rather should be analyzed under the “Rule of Reason” test to determine whether they violate the federal antitrust laws. This holding has resulted in heightened scrutiny of such settlement agreements by the FTC and state and local authorities, and has increased the risk of liability in pending antitrust litigation brought by private plaintiffs. The FTC has brought actions against parties to such settlement agreements, including us, and we have become subject to increased FTC investigations or enforcement actions arising from such settlement agreements. Further, private plaintiffs, including direct and indirect purchasers of our products, have also become more active in bringing private litigation claims against us and other brand and generic/biosimilar pharmaceutical companies alleging that such settlement agreements violate the antitrust laws. Accordingly, we have in the past received and may receive formal or informal requests from the FTC for information about a particular settlement agreement, and there is a risk that the FTC, state and local authorities, or private plaintiffs, may commence an action against us alleging violations of the antitrust laws. We have been and are currently involved in private antitrust actions involving certain settlement agreements as described in Note 21. Commitments and Contingencies - Other Litigation Related to the Company's Business.
Assistant: